Welcome to my first Medicines Manufacturing Industry Partnership (MMIP) update. Throughout 2016 we intend to share more of our activities as we build the medicines manufacturing community voice and promote the drive for growth of medicines manufacturing in the UK.
As a way to help us to connect with you and give more detail about what we do and our work, we have prepared with the Association of the British Pharmaceutical Industry (ABPI), BioIndustry Association (BIA) and Knowledge Transfer Network (KTN) an MMIP overview leaflet which can be accessed here.
At the joint MHRA/ABPI Making the case for UK medicines manufacturing conference in early March, MMIP shared some of our 2015 successes such as:
- helping to secure funding for ADDoPT (digital design for small molecule formulation)
- launch by the KTN of the Medicines Manufacturing Landscape tool
- supporting the publication and promotion of MHRA Innovation office case studies
- input into the Science Industry Partnership’s Skills Strategy
- together with the BIA submitting a fiscal paper on capital allowances and establishing measures for our sector value (GVA)
We also shared the MMIP’s 2016 operating plan. This included work-streams focusing on Technology & Innovation, the Business Environment, the Regulatory Environment and Skills. The focus of these work-streams is on enabling growth in manufacturing as part of our end to end supply chains.
We see three groupings of medicines manufacturing, ‘small molecules’, ‘large molecules‘ and advanced therapies. In all of these, the end to end supply chain is critical to the manufacturing success. With this in mind, a ministerial taskforce has been set up, co-chaired by me and George Freeman, Minister for Life Sciences. This taskforce is focused on making recommendations to anchor the manufacture of advanced therapy medicinal products in the UK. It had its first meeting on Tuesday 22 March and more information will be coming soon on its terms of reference, scope and next steps focusing on manufacturing capability and technology, skills, and international competitiveness.
During my key note address at the conference, I outlined the challenge we face in the UK from competing regions. We already have a rich landscape of capability and infrastructure in the UK with national centres and renowned academic research but in an increasingly competitive world, we must offer more to encourage medicines manufacturing in the UK. In this respect, our regulator MHRA is a unique asset in supporting companies that have developed novel medicines or development approaches in their regulation.
I was very encouraged and excited by the alignment of industry, trade bodies and MHRA and the passion there is for the UK medicines manufacturing industry to succeed. We have many of the pieces of our jigsaw already available and with some effort and energy we can push them together to complete the picture and make the UK a more vibrant place to invest in medicines manufacturing.
Future sector MMIP events will be on Digital Design, Continuous Manufacturing and Patient Centric Packaging. We will contact you with more details on these and the opportunity to get involved.
I hope you find this note of interest and we will continue to communicate and create a community of committed likeminded professionals who can help with MMIP. Please contact us at MMIP@bioindustry.org or join our LinkedIn group at http://bia.me/MMIP_LinkedIn. Likewise, if you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or sign up to our mailing list here.
Chairman, Medicines Manufacturing Industry Partnership